|
|
Article: Second Phase III Study of Avastin Plus Chemotherapy Shows Improved Progression-Free Survival in Women with Advanced HER2-Negative Breast Cancer.
- Article from:
- Business Wire
- Article date:
- May 31, 2008
CopyrightCOPYRIGHT 2008 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
- Positive AVADO Results Support Efficacy and Safety of Avastin in First-Line Metastatic Breast Cancer -
CHICAGO -- Genentech, Inc. (NYSE:DNA) today announced that Avastin([R]) (bevacizumab), in combination with docetaxel chemotherapy, significantly increased the time women with metastatic breast cancer receiving first-line therapy lived without their disease advancing, as defined by the primary endpoint of progression-free survival (PFS). In this Roche-sponsored, placebo-controlled Phase III trial (AVADO), two dose levels of Avastin in combination with docetaxel chemotherapy showed a statistically significant improvement in PFS compared to docetaxel chemotherapy ...